Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493300 | 0.88 | TAS1R3 (0.60) | TAS1R3TAS1R1CREBBPTSHRALDH1A1 | |
| SCHEMBL17991554 | 0.87 | MGLL (0.56) | TAS1R3TAS1R1MGLLGAAALDH1A1 | |
| SCHEMBL10958234 | 0.87 | NOTUM (0.56) | TAS1R3TAS1R1MGLLCREBBPTSHR | |
| SCHEMBL1808476 | 0.86 | TSHR (0.63) | CREBBPTSHRALDH1A1MAPK1MAPT | |
| SCHEMBL14926458 | 0.84 | MGLL (0.64) | MGLLALDH1A1TDP1L3MBTL1 | |
| SCHEMBL25314236 | 0.84 | TDP1 (0.57) | TAS1R3TAS1R1MGLLGAAALDH1A1 | |
| SCHEMBL12492829 | 0.84 | ALDH1A1 (0.55) | TAS1R3TAS1R1MGLLGAAALDH1A1 | |
| SCHEMBL1495947 | 0.84 | MEN1 (0.51) | MGLLTSHRGAAALDH1A1MAPT | |
| SCHEMBL6381826 | 0.83 | MAPK1 (0.67) | CREBBPTSHRMAPK1MAPTL3MBTL1 | |
| SCHEMBL18655509 | 0.83 | CA12 (0.61) | CREBBPTSHRGAAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | TAS1R3 2409/4885TAS1R1 1251/4885MGLL 1975/4885 |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TAS1R3 322/4885TAS1R1 325/4885MGLL 4509/4885 |
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | WDR5, WDR1, WDR3 | TAS1R3 3870/4885TAS1R1 3523/4885MGLL 3182/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | TAS1R3 1790/4885TAS1R1 1017/4885MGLL 1621/4885 |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | TAS1R3 3870/4885TAS1R1 3523/4885MGLL 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.